240 filings
ARS
2023 FY
SNDX
Syndax Pharmaceuticals Inc
2 Apr 24
Annual report to shareholders
4:30pm
DEFA14A
SNDX
Syndax Pharmaceuticals Inc
2 Apr 24
Additional proxy soliciting materials
4:02pm
DEF 14A
SNDX
Syndax Pharmaceuticals Inc
Definitive proxy
2 Apr 24
4:00pm
8-K
SNDX
Syndax Pharmaceuticals Inc
18 Mar 24
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
7:10am
S-3ASR
SNDX
Syndax Pharmaceuticals Inc
27 Feb 24
Automatic shelf registration
5:28pm
S-8
qc53z
27 Feb 24
Registration of securities for employees
5:21pm
8-K
w9f53eww9ww
27 Feb 24
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
4:03pm
8-K
q4j5or6y9g04p5m6a
20 Dec 23
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
8:40am
8-K
ski9saxuq9
15 Dec 23
Entry into a Material Definitive Agreement
5:29pm
424B5
ts4zgm04sximbf8y8h
15 Dec 23
Prospectus supplement for primary offering
5:29pm
424B5
rw89sg
14 Dec 23
Prospectus supplement for primary offering
4:30pm
8-K
jq6npv
12 Dec 23
Other Events
4:05pm
UPLOAD
xsc 68nr4mfx
7 Dec 23
Letter from SEC
12:00am
CORRESP
fmztcq6y4g24cvs 1cmf
28 Nov 23
Correspondence with SEC
12:00am
UPLOAD
q6xqzqry7t4l1v qkc
13 Nov 23
Letter from SEC
12:00am
8-K
4xk7 nr7ik3a
2 Nov 23
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
4:03pm
8-K
fuo2sh6b2rhz
2 Oct 23
Other Events
7:04am